3.4.17.23	all-trans retinoic acid	-	679704	
3.4.17.23	8-[[2-(dimethylamino)ethyl]amino]-5-(hydroxymethyl)-9-oxo-9H-xanthen-2-yl 4-methylbenzenesulfonate	enhances ACE2 activity in a dose-dependent manner and causes considerable reductions in blood pressure and a striking reversal of cardiac and renal fibrosis in the spontaneously hypertensive rat model of hypertension	692586	
3.4.17.23	resorcinolnaphthalein	enhances ACE2 activity in a dose-dependent manner	692586	
3.4.17.23	losartan	an angiotensin II type 1 receptor blocker, increases central ACE2 activity. Losartan also restores brain ACE2 activity in transgenic RA mice, overview	708683	
3.4.17.23	additional information	no activation by PD123319, an angiotensin II type 2 antagonist	708683	
3.4.17.23	XNT	activates ACE2, reduces platelet attachment to injured vessels, reduces thrombus size, and prolonges the time for complete vessel occlusion in mice. Thrombus area is reduced by 60%, whereas time for thrombus formation is prolonged by 45% in XNT-treated mice	709990	
3.4.17.23	XNT	treatment at 10 mg/kg resultes in a 30% attenuation of thrombus formation in the SHR	709990	
3.4.17.23	losartan	a specific angiotensin II receptor antagonist, is a well-known antihypertensive drug with a potential role in positively regulating ACE2 in the lung	710616	
3.4.17.23	D-glucose	incubation of cells in high D-glucose increases ACE2 activity	732775	
3.4.17.23	SARS-CoV-2	ACE2 cleavage of des-Arg9-bradykinin substrate analogue is markedly accelerated by SARS-CoV-2 infection, while cleavage of angiotensin II analogue is minimally affected by the binding of spike protein	763217